Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer
The real-world outcomes of patients with metastatic prostate cancer (mPCa) are largely unexplored. We investigated the trends in overall survival (OS) and cancer-specific survival (CSS) in patients with de novo mPCa according to distinct time periods. The U.S. Surveillance, Epidemiology, and End Res...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-10-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/10/2855 |
| _version_ | 1797551822904229888 |
|---|---|
| author | Carlo Cattrini Davide Soldato Alessandra Rubagotti Linda Zinoli Elisa Zanardi Paola Barboro Carlo Messina Elena Castro David Olmos Francesco Boccardo |
| author_facet | Carlo Cattrini Davide Soldato Alessandra Rubagotti Linda Zinoli Elisa Zanardi Paola Barboro Carlo Messina Elena Castro David Olmos Francesco Boccardo |
| author_sort | Carlo Cattrini |
| collection | DOAJ |
| description | The real-world outcomes of patients with metastatic prostate cancer (mPCa) are largely unexplored. We investigated the trends in overall survival (OS) and cancer-specific survival (CSS) in patients with de novo mPCa according to distinct time periods. The U.S. Surveillance, Epidemiology, and End Results (SEER) Research Data (2000–2017) were analyzed using the SEER*Stat software. The Kaplan–Meier method and Cox regression were used. Patients with de novo mPCa were allocated to three cohorts based on the year of diagnosis: A (2000–2003), B (2004–2010), and C (2011–2014). The maximum follow-up was fixed to 5 years. Overall, 26,434 patients were included. Age, race, and metastatic stage (M1) significantly affected OS and CSS. After adjustment for age and race, patients in Cohort C showed a 9% reduced risk of death (hazard ratio (HR): 0.91 (95% confidence interval [CI] 0.87–0.95), <i>p</i> < 0.001) and an 8% reduced risk of cancer-specific death (HR: 0.92 (95% CI 0.88–0.96), <i>p</i> < 0.001) compared with those in Cohort A. After adjustment for age, race, and metastatic stage, patients in Cohort C showed an improvement in OS and CSS compared with Cohort B (HR: 0.94 (95% CI 0.91–0.97), <i>p</i> = 0.001; HR: 0.89 (95% CI 0.85–0.92), <i>p</i> < 0.001). Patients with M1c disease had a more pronounced improvement in OS and CSS compared with the other stages. No differences were found between Cohorts B and C. In conclusion, the real-world survival of de novo mPCa remains poor, with a median OS and CSS improvement of only 4 months in the latest years. |
| first_indexed | 2024-03-10T15:51:34Z |
| format | Article |
| id | doaj.art-2d5e92c00f474f6da552bd5fbc57a2d1 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T15:51:34Z |
| publishDate | 2020-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-2d5e92c00f474f6da552bd5fbc57a2d12023-11-20T15:58:05ZengMDPI AGCancers2072-66942020-10-011210285510.3390/cancers12102855Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate CancerCarlo Cattrini0Davide Soldato1Alessandra Rubagotti2Linda Zinoli3Elisa Zanardi4Paola Barboro5Carlo Messina6Elena Castro7David Olmos8Francesco Boccardo9Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genoa, 16132 Genoa, ItalyDepartment of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genoa, 16132 Genoa, ItalyAcademic Unit of Medical Oncology, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, ItalyAcademic Unit of Medical Oncology, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, ItalyDepartment of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genoa, 16132 Genoa, ItalyAcademic Unit of Medical Oncology, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, ItalyDepartment of Medical Oncology, Santa Chiara Hospital, 38122 Trento, ItalyCNIO-IBIMA Genitourinary Cancer Unit, Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Instituto de Investigación Biomédica de Málaga, 29010 Malaga, SpainProstate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, SpainDepartment of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genoa, 16132 Genoa, ItalyThe real-world outcomes of patients with metastatic prostate cancer (mPCa) are largely unexplored. We investigated the trends in overall survival (OS) and cancer-specific survival (CSS) in patients with de novo mPCa according to distinct time periods. The U.S. Surveillance, Epidemiology, and End Results (SEER) Research Data (2000–2017) were analyzed using the SEER*Stat software. The Kaplan–Meier method and Cox regression were used. Patients with de novo mPCa were allocated to three cohorts based on the year of diagnosis: A (2000–2003), B (2004–2010), and C (2011–2014). The maximum follow-up was fixed to 5 years. Overall, 26,434 patients were included. Age, race, and metastatic stage (M1) significantly affected OS and CSS. After adjustment for age and race, patients in Cohort C showed a 9% reduced risk of death (hazard ratio (HR): 0.91 (95% confidence interval [CI] 0.87–0.95), <i>p</i> < 0.001) and an 8% reduced risk of cancer-specific death (HR: 0.92 (95% CI 0.88–0.96), <i>p</i> < 0.001) compared with those in Cohort A. After adjustment for age, race, and metastatic stage, patients in Cohort C showed an improvement in OS and CSS compared with Cohort B (HR: 0.94 (95% CI 0.91–0.97), <i>p</i> = 0.001; HR: 0.89 (95% CI 0.85–0.92), <i>p</i> < 0.001). Patients with M1c disease had a more pronounced improvement in OS and CSS compared with the other stages. No differences were found between Cohorts B and C. In conclusion, the real-world survival of de novo mPCa remains poor, with a median OS and CSS improvement of only 4 months in the latest years.https://www.mdpi.com/2072-6694/12/10/2855prostatic neoplasms/mortalityprostatic neoplasms/epidemiologySEER Program |
| spellingShingle | Carlo Cattrini Davide Soldato Alessandra Rubagotti Linda Zinoli Elisa Zanardi Paola Barboro Carlo Messina Elena Castro David Olmos Francesco Boccardo Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer Cancers prostatic neoplasms/mortality prostatic neoplasms/epidemiology SEER Program |
| title | Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer |
| title_full | Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer |
| title_fullStr | Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer |
| title_full_unstemmed | Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer |
| title_short | Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer |
| title_sort | epidemiological characteristics and survival in patients with de novo metastatic prostate cancer |
| topic | prostatic neoplasms/mortality prostatic neoplasms/epidemiology SEER Program |
| url | https://www.mdpi.com/2072-6694/12/10/2855 |
| work_keys_str_mv | AT carlocattrini epidemiologicalcharacteristicsandsurvivalinpatientswithdenovometastaticprostatecancer AT davidesoldato epidemiologicalcharacteristicsandsurvivalinpatientswithdenovometastaticprostatecancer AT alessandrarubagotti epidemiologicalcharacteristicsandsurvivalinpatientswithdenovometastaticprostatecancer AT lindazinoli epidemiologicalcharacteristicsandsurvivalinpatientswithdenovometastaticprostatecancer AT elisazanardi epidemiologicalcharacteristicsandsurvivalinpatientswithdenovometastaticprostatecancer AT paolabarboro epidemiologicalcharacteristicsandsurvivalinpatientswithdenovometastaticprostatecancer AT carlomessina epidemiologicalcharacteristicsandsurvivalinpatientswithdenovometastaticprostatecancer AT elenacastro epidemiologicalcharacteristicsandsurvivalinpatientswithdenovometastaticprostatecancer AT davidolmos epidemiologicalcharacteristicsandsurvivalinpatientswithdenovometastaticprostatecancer AT francescoboccardo epidemiologicalcharacteristicsandsurvivalinpatientswithdenovometastaticprostatecancer |